Last reviewed: June 7, 2026

Last updated: June 7, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Semaglutide's journey from laboratory discovery to household weight loss medication spans nearly 30 years of pharmaceutical innovation. The drug received FDA approval for type 2 diabetes in 2017 and weight management in 2021, fundamentally reshaping how millions approach metabolic health. Understanding this history helps patients make informed decisions about their treatment options today.

The Origins of Semaglutide Development

Novo Nordisk scientists began exploring glucagon-like peptide-1 (GLP-1) receptor agonists in the 1990s, building on earlier research showing how GLP-1 influences blood sugar and appetite. The company recognized that modifying the GLP-1 molecule could create a longer-acting therapeutic compound. This led to semaglutide's chemical synthesis and early laboratory testing throughout the 2000s.

Early clinical trials in the 2010s demonstrated that semaglutide outperformed existing diabetes medications by improving both glycemic control and body weight. Researchers found that the medication triggered sustained satiety signals in the brain while simultaneously improving insulin sensitivity. These dual mechanisms caught the attention of weight management specialists, who began studying semaglutide specifically for obesity treatment in non-diabetic patients.

FDA Approval Timeline for Diabetes and Weight Loss

The FDA granted approval for semaglutide (Ozempic brand) as a weekly injection for type 2 diabetes on December 5, 2017. This marked the first major regulatory milestone for the compound. Clinical trials showed that Ozempic reduced A1C levels by up to 1.8% and lowered cardiovascular mortality risk in high-risk diabetic patients.

Weight loss applications emerged next. In 2021, the FDA approved a higher-dose weekly semaglutide injection marketed as Wegovy specifically for chronic weight management in adults with obesity or overweight with weight-related conditions. Pivotal STEP trials demonstrated average weight loss of 15-18% of baseline body weight over 68 weeks—significantly higher than traditional behavioral approaches alone. This approval transformed semaglutide from a diabetes medication into a mainstream obesity treatment.

Market Growth and Real-World Impact on Weight Management

Semaglutide's approval sparked unprecedented demand for GLP-1 therapy. By 2023, millions of prescriptions had been filled globally, creating widespread shortages and waitlists. Media coverage and celebrity adoption accelerated public awareness, though it also led to off-label use and supply chain stress that affected patients with genuine medical need.

The medication's real-world effectiveness transformed obesity medicine outcomes. Observational studies documented sustained weight loss maintenance, improved metabolic markers, and better quality-of-life metrics in treated populations. Healthcare systems recognized semaglutide as a cost-effective intervention compared to obesity-related complications like type 2 diabetes, cardiovascular disease, and joint deterioration.

Compounded Semaglutide as an Accessible Alternative

Licensed 503A compounding pharmacies began producing semaglutide preparations in response to brand-name shortages and pricing barriers. PlexusDx partners exclusively with compounding facilities that meet rigorous pharmaceutical standards. Compounded semaglutide injection costs significantly less than Wegovy or Ozempic while maintaining identical active-ingredient efficacy.

PlexusDx offers compounded semaglutide injection starting at $149 per month across all commitment tiers—with the clinical principle that your dose may need to go up, but your price won't. The program serves all 50 states without insurance requirements or membership fees, making GLP-1 therapy accessible to patients regardless of insurance status. HSA and FSA accounts can cover the medication, further reducing out-of-pocket costs for eligible patients.

Genetic Factors Influencing Semaglutide Response

Not all patients respond identically to semaglutide due to variations in GLP-1 receptor genetics and metabolic pathways. Research has identified specific genetic polymorphisms—including GLP1R rs6923761 and GIPR rs1800437—that correlate with differential medication response. Some individuals achieve 20%+ weight loss while others experience more modest results, partly reflecting these underlying genetic differences.

PlexusDx offers the Precision Peptide Genetic Test ($99 add-on after first treatment month) to identify individual variations across 14 metabolic pathways and 49 peptides. This test examines genetic predispositions in GLP-1 signaling, appetite regulation, and energy metabolism—allowing clinicians to predict who will respond optimally to semaglutide versus dual-pathway compounds like tirzepatide. Personalization based on genetics represents the evolution of precision medicine from Ozempic's original one-size-fits-most approach.

The Evolution Beyond Single-Agent Semaglutide

Following semaglutide's success, researchers developed dual-pathway medications like tirzepatide that activate both GLP-1 and GIP receptors simultaneously. Tirzepatide demonstrated superior weight loss (up to 22% in clinical trials) compared to semaglutide alone. This innovation expanded the therapeutic toolkit for patients who achieve suboptimal results with monotherapy.

PlexusDx recognizes that treatment requires individualization. Beyond compounded semaglutide, the platform offers oral semaglutide, compounded tirzepatide injection, oral tirzepatide, and GLP-Squared dual-pathway compounds. Starting at $249 monthly, tirzepatide options serve patients needing additional metabolic intervention. The Precision Peptide Genetic Test helps guide these treatment choices by identifying which peptide pathways show strongest activation potential in each individual.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

When was Ozempic first approved by the FDA?

The FDA approved semaglutide (Ozempic brand) for type 2 diabetes on December 5, 2017. A higher-dose formulation marketed as Wegovy received weight management approval in 2021. Both are the same active compound—semaglutide—dosed differently depending on the indication.

How much weight do most people lose with semaglutide?

Clinical STEP trials showed average weight loss of 15-18% of baseline body weight over 68 weeks with semaglutide treatment. Individual results vary significantly based on genetics, lifestyle adherence, and metabolic factors. PlexusDx's Precision Peptide Genetic Test helps predict individual response potential by analyzing GLP1R and related genetic variants.

Is compounded semaglutide as effective as Ozempic or Wegovy?

Compounded semaglutide contains the identical active ingredient as brand-name Ozempic and Wegovy, manufactured by licensed 503A compounding pharmacies. Efficacy depends on proper dosing and consistent use, not brand. PlexusDx compounded semaglutide starts at $149 monthly, offering equivalent treatment at a fraction of brand-name costs.

What are the common side effects of semaglutide?

Gastrointestinal effects—nausea, vomiting, diarrhea, constipation—occur in 20-60% of users depending on dose escalation speed. Most side effects diminish within weeks as the body adapts. Serious adverse events are rare; pancreatitis and gallbladder issues occur in less than 1% of treated patients. Starting at a low dose and titrating gradually minimizes intolerance.

How does genetic testing help choose between semaglutide and tirzepatide?

PlexusDx's Precision Peptide Genetic Test examines variants in GLP1R, GIPR, FTO, and MC4R genes across 14 metabolic pathways. Patients with strong GLP-1 receptor signaling may respond optimally to semaglutide ($149/mo), while those with weaker GLP-1 pathways but robust GIP sensitivity may benefit from tirzepatide's dual action ($249/mo). Personalization predicts better outcomes and cost-effectiveness.

Related Reading

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves